Document is current

Any future updates will be listed below

The metabolic dysfunction-associated steatohepatitis (MASH) drug resmetirom exhibits broad nuclear receptor activity with minimal functional impact

Crossref DOI link: https://doi.org/10.1038/s41598-026-37494-y

Published Online: 2026-01-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark